# Cambridge Brain Mets Trial 1

> **NCT02768337** · PHASE1,PHASE2 · TERMINATED · sponsor: **Cambridge University Hospitals NHS Foundation Trust** · enrollment: 26 (actual)

## Conditions studied

- Lung Cancer
- Breast Cancer
- Brain Cancer
- Advanced Breast Cancer
- Advanced Lung Cancer

## Interventions

- **DRUG:** Afatinib
- **RADIATION:** 2 Gy targeted radiotherapy
- **RADIATION:** 4 Gy targeted radiotherapy

## Key facts

- **NCT ID:** NCT02768337
- **Lead sponsor:** Cambridge University Hospitals NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03-10
- **Primary completion:** 2020-08-12
- **Final completion:** 2021-08-12
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2024-01-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02768337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02768337, "Cambridge Brain Mets Trial 1". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02768337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*